Description
Pimobendanisacardiovasculardrugcommonlyusedtotreatcongestiveheartfailure,dilatedcardiomyopathy,andchronicvalvularheartdiseaseinveterinarymedicine.Thiscompoundexhibitsvasodilatoryandantithromboticactivities,decreasingperipheralresistanceandinhibitingplateletaggregation.PimobendanselectivelyinhibitscardiacphosphodiesteraseIII(PDE3),increasingmyocardialcAMPandcausingpositiveinotropiceffectssuchasanincreaseinheartrate,leftventriclesystolicpressure,andleftventriclefillingpressure,andadecreaseinperipheralresistance(meanarterialpressure).
References
ShipleyEA,HoganDF,FiakpuiNN,etal.Invitroeffectofpimobendanonplateletaggregationindogs.AmJVetRes.2013Mar;74(3):403-7.PMID:23438115.
BoyleKL,LeechE.Areviewofthepharmacologyandclinicalusesofpimobendan.JVetEmergCritCare(SanAntonio).2012Aug;22(4):398-408.PMID:22928748.
VerdouwPD,HartogJM,DunckerDJ,etal.Cardiovascularprofileofpimobendan,abenzimidazole-pyridazinonederivativewithvasodilatingandinotropicproperties.EurJPharmacol.1986Jul15;126(1-2):21-30.PMID:2875884.
ScholzH,MeyerW.Phosphodiesterase-inhibitingpropertiesofnewerinotropicagents.Circulation.1986Mar;73(3Pt2):III99-108.PMID:2417748.